Hsieh, PhD, a partner and biotechnology analyst with William Blair, and a colleague were similarly positive in a research note: Orforglipron outperformed investor expectations in patients living with both overweight/obesity and type 2 diabetes, which we view as the higher-risk and more difficult-to-treat population. Mini-surge Investors agreed with those upbeat assessments, touching off a mini-surge that sent Lilly shares rising 6% Tuesday, from $695.33 to $736.03
Most weight loss specialists recommend choosing one primary medication rather than layering both, since tirzepatide's efficacy typically exceeds combination therapy outcomes in clinical practice
Finding out you're pregnant (congratulations, by the way!) comes with a laundry list of no-dont-touch-that and it-could-be-bad-for-the-baby warning labels slapped across various beauty products
Vitamin D deficiency, important for bone health, which is a concern for those receiving frequent blood transfusions
10.1007/s40291-018-0322-3 125 ParasarP.OzcanP.TerryK